FDA Clears AI Tool to Predict Breast Cancer Recurrence Before Surgery
The FDA has cleared TumorSight Risk, an AI tool that predicts breast cancer recurrence using existing MRI data. Developed by SimBioSys and powered by NVIDIA, it provides risk scores before surgery, helping patients and doctors tailor treatment plans.